Cargando…

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis

OBJECTIVE: Autologous hematopoietic stem cell transplantation (aHSCT) is increasingly recognized as a potential therapy for patients with highly active multiple sclerosis (MS). This study aims to assess outcome differences in disease activity in MS patients treated either with aHSCT or alemtuzumab....

Descripción completa

Detalles Bibliográficos
Autores principales:	Häußler, Vivien, Ufer, Friederike, Pöttgen, Jana, Wolschke, Christine, Friese, Manuel A., Kröger, Nicolaus, Heesen, Christoph, Stellmann, Jan‐Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164852/ https://www.ncbi.nlm.nih.gov/pubmed/33949790 http://dx.doi.org/10.1002/acn3.51366

Ejemplares similares

Reduced prefrontal cortex and sympathetic nervous system activity correlate with fatigue after aHSCT
por: Boberg, Erik, et al.
Publicado: (2021)

Stammzelltransplantation bei Multipler Sklerose - wo stehen wir?
por: Heesen, Christoph, et al.
Publicado: (2022)

R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement
por: Steinhardt, Maximilian J., et al.
Publicado: (2021)

2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
por: Perreault, Sarah, et al.
Publicado: (2023)

NEDA—NEutron Detector Array
por: Valiente-Dobón, J J, et al.
Publicado: (2019)

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

Challenges and Opportunities for Biomarkers of Clinical Response to AHSCT in Autoimmunity
por: Harris, Kristina M., et al.
Publicado: (2018)

Smartphone Accelerometry: A Smart and Reliable Measurement of Real-Life Physical Activity in Multiple Sclerosis and Healthy Individuals
por: Zhai, Yuyang, et al.
Publicado: (2020)

Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis
por: Rotstein, Dalia, et al.
Publicado: (2022)

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
por: Burns, D M, et al.
Publicado: (2016)

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis
por: Mohammadi, Reihane, et al.
Publicado: (2021)

Introducing a new method to assess vision: Computer-adaptive contrast-sensitivity testing predicts visual functioning better than charts in multiple sclerosis patients
por: Stellmann, JP, et al.
Publicado: (2015)

No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts
por: Pandit, Lekha
Publicado: (2019)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT
por: Bonechi, Elena, et al.
Publicado: (2014)

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients
por: Bertolotto, Antonio, et al.
Publicado: (2020)

Frequent neurocognitive deficits after recovery from mild COVID-19
por: Woo, Marcel S, et al.
Publicado: (2020)

Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMS—understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial
por: Schiffmann, Insa, et al.
Publicado: (2020)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis
por: Londoño, Ana C., et al.
Publicado: (2017)

Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
por: Kvistad, Silje Agnethe Stokke, et al.
Publicado: (2022)

Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability
por: Has Silemek, Arzu Ceylan, et al.
Publicado: (2020)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Arm Ergometry to Improve Mobility in Progressive Multiple Sclerosis (AMBOS)—Results of a Pilot Randomized Controlled Trial
por: Heinrich, Inga, et al.
Publicado: (2021)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2019)

Impairment and restrictions in possibly benign multiple sclerosis
por: Schaefer, Laura Melanie, et al.
Publicado: (2019)

The New Neutron Multiplicity Filter NEDA and Its First Physics Campaign with AGATA
por: Jaworski, G, et al.
Publicado: (2019)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
por: Gagelmann, Nico, et al.
Publicado: (2021)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

A Preliminary Study on the Meaning of Inflammatory Indexes in MS: A Neda-Based Approach
por: Bunul, Sena Destan, et al.
Publicado: (2023)

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
por: Arnold, Douglas L., et al.
Publicado: (2016)

Clinical predictors of NEDA-3 one year after diagnosis of pediatric multiple sclerosis: an exploratory single-center study
por: Palavra, Filipe, et al.
Publicado: (2023)

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
por: Amato, Maria Pia, et al.
Publicado: (2023)

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]
por: Newsome, Scott D., et al.
Publicado: (2023)

Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing–remitting MS
por: Stellmann, Jan‐Patrick, et al.
Publicado: (2016)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ntu8kcomod2fdmnfk5hjbpvfog